New Delhi, February 27 Drug maker Lupin announced on Friday that it has received an Establishment Inspection Report (EIR) from the US health regulator for its manufacturing facility in Goa.
The company stated that it has received the EIR with a satisfactory Voluntary Action Indicated (VAI) classification.
The EIR was issued following an inspection of the facility from November 10-21, 2025.
The US Food and Drug Administration (USFDA) issues an EIR when it closes the inspection of an establishment that is subject to FDA or FDA-contracted scrutiny.
"This outcome reflects our continued focus on quality excellence and regulatory compliance, reinforcing our commitment to delivering safe and effective medicines to patients worldwide," Lupin MD Nilesh Gupta said in a statement.
Shares of the company were trading up 0.24 per cent at Rs 2,328.70 apiece on BSE.
